

**Allopurinol**

Section	Indications
Supportive medicines Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

**Mesna**

Section	Indications
Supportive medicines Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule Oral > Solid: 400 mg; 600 mg	<p>Osteosarcoma of bone and articular cartilage of other specified sites</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Germ cell tumour of testis</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Rhabdomyosarcoma primary site</p> <p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p>

**Rasburicase**

Section	Indications
Supportive medicines Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution	Tumour lysis syndrome

**Zoledronic acid**

Section	Indications
Supportive medicines Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow